Deals
CVS-Aetna Deal May Hinge on Antitrust Approach Under Trump
- Companies announced $67.5 billion takeover on Sunday
- Aetna shares trade below $207 price, signaling investor worry
This article is for subscribers only.
CVS Health Corp.’s $67.5 billion takeover of Aetna Inc. will test the Trump administration’s approach to far-reaching corporate takeovers, just weeks after the U.S. government sued to block a major telecommunications merger.
The health-care deal unveiled Sunday would create an industry giant with over $240 billion in annual sales with a hand in insurance, prescription drug plan administration, retail pharmacies and corner clinics. The companies said the combination will save $750 million in costs and bring consumers better, more efficient health care.